Mirum Pharmaceuticals, Inc. - common stock (MIRM): Price and Financial Metrics


Mirum Pharmaceuticals, Inc. - common stock (MIRM)

Today's Latest Price: $18.05 USD

1.20 (-6.23%)

Updated Jan 27 4:00pm

Add MIRM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MIRM Stock Price Chart Interactive Chart >

Price chart for MIRM

MIRM Price/Volume Stats

Current price $18.05 52-week high $27.43
Prev. close $19.25 52-week low $9.14
Day low $17.86 Volume 119,335
Day high $19.24 Avg. volume 171,720
50-day MA $20.20 Dividend yield N/A
200-day MA $19.50 Market Cap 464.19M

Mirum Pharmaceuticals, Inc. - common stock (MIRM) Company Bio


Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.


MIRM Latest News Stream


Event/Time News Detail
Loading, please wait...

MIRM Latest Social Stream


Loading social stream, please wait...

View Full MIRM Social Stream

Latest MIRM News From Around the Web

Below are the latest news stories about Mirum Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIRM as an investment opportunity.

Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign

Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness Campaign

Yahoo | January 24, 2021

Mirum kicks off enrolment in Phase 2b VISTAS study of volixibat

Mirum Pharmaceuticals ([[MIRM]] +1.1%) announces that the first patient has been enrolled in its Phase 2b VISTAS study evaluating volixibat in adult patients with primary sclerosing cholangitis ((PSC)), an idiopathic chronic cholestatic liver disease.Volixibat, an oral, minimally absorbed medication, is designed to offer a novel approach in the treatment of adult...

Seeking Alpha | January 14, 2021

Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing Cholangitis

Mirum Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients with Primary Sclerosing Cholangitis

Yahoo | January 14, 2021

Mirium Pharmaceuticals +4%, provides corporate update

Mirum Pharmaceuticals ([[MIRM]] +4.1%) completes of maralixibat rolling NDA targeted for Q1 2021Company expects first-patient-in for volixibat studies in ICP and PSC, and maralixibat study in biliary atresia in Q1 2021.Launching volixibat primary biliary cholangitis program in H2 2021European commercial leader hired in anticipation of potential approval of maralixibat.Cash, cash...

Seeking Alpha | January 12, 2021

Mirum Pharmaceuticals Provides Corporate Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Corporate Update

Business Wire | January 12, 2021

Read More 'MIRM' Stories Here

MIRM Price Returns

1-mo 1.63%
3-mo 11.90%
6-mo -18.25%
1-year -0.22%
3-year N/A
5-year N/A
YTD 3.38%
2020 -28.79%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8567 seconds.